Nedosiran for Primary Hyperoxaluria
(PHYOX8 Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing nedosiran, a medication, in children with a rare kidney condition called Primary Hyperoxaluria. The goal is to see if it can reduce harmful oxalate levels and protect their kidneys.
Research Team
Sarb Shergill, PhD
Principal Investigator
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Eligibility Criteria
This trial is for children from birth to 11 years with Primary Hyperoxaluria (PH), a genetic disorder affecting the kidneys, who have normal or near-normal kidney function. Participants need a legal guardian to consent and help with study requirements, must not be pregnant or breastfeeding if applicable, and should be on stable PH treatment for at least 3 months.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive monthly subcutaneous injections of DCR-PHXC based on age and weight
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- nedosiran
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Lead Sponsor
Dicerna Pharmaceuticals, Inc.
Lead Sponsor